Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia

Authors not listed

Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · 2014

Abstract

This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2014). A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia. <em>Chase Pharmaceuticals Corporation, an affiliate of Allergan plc</em>. https://clinicaltrials.gov/study/NCT02185053
Vancouver
Anonymous. A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia. Chase Pharmaceuticals Corporation, an affiliate of Allergan plc. 2014.
BibTeX
@misc{anon2014APhase, title = {A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia}, author = {Anonymous}, journal = {Chase Pharmaceuticals Corporation, an affiliate of Allergan plc}, year = {2014}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings